Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drozitumab in Previously Untreated Advanced Non-Small Cell Lung Cancer
NCT00480831Phase 2Completed
- Sponsor
- Genentech
- Start
- Jun 2007
- Primary completion
- Aug 2010
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of Apomab in non-small cell lung cancer (NSCLC), sponsored by Genentech. Started Jun 2007; status: completed.
02
Drugs
Apomab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00480831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00480831.